IRF5-CPP5
Based on 1 Customer Validation
IRF5-CPP5 is a cytosolic peptide that selectively targeting human IRF5 wirh a Kd of 0.53 μM. IRF5-CPP5 disrupts IRF5 homodimerization and inhibits its nuclear translocation without altering IRF5 phosphorylation levels. IRF5-CPP5 inhibits proinflammatory cytokine (IL-6, IL-1β, TNF-α) production. IRF5-CPP5 can be used for the research of systemic lupus erythematosus.
For research use only. We do not sell to patients.
- Purity : 99.23%
- CAS No.: 1601299-92-6
- Formula: C160H245N37O36S
- Molecular Weight:3294.95
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biological Activity
Description
IC50 & Target
[1]|
IL-6 |
IL-1β |
In Vitro
IRF5-CPP5 binds to recombinant monomeric IRF5 (222 to 425) with a submicromolar Kd of 0.53 μM[1].
IRF5-CPP5 inhibits homodimerization of recombinant full-length IRF5 S430D and WT variants with IC50 values of 15.3 and 15.4 μM[1].
IRF5-CPP5 (1-10 μM; 1 h) dose-dependently inhibits R848 (HY-13740 -induced endogenous IRF5 homodimerization in THP-1 human monocytic cells[1].
IRF5-CPP5 (5 μM; 30-60 min) penetrates and colocalizes with endogenous IRF5 in human primary CD19+ B cells, CD14+ monocytes, and BDCA2+ CD123+ pDCs[1].
IRF5-CPP5 (0.62-50 μM; 30 min) concentration-dependently inhibits R848-induced IL12p40 production in human primary PBMCs[1].
IRF5-CPP5 (0.62-16.07 μM) concentration-dependently inhibits R848-induced IRF5 nuclear translocation in human primary CD14+ monocytes and CD19+ B cells[1].
IRF5-CPP5 (3.5-15 μM; 1 h) significantly inhibits LPS(HY-D1056) - and R848-induced proinflammatory cytokine (IL-6, IL-1β, TNF-α) production and transcript expression in human primary MDMs[1].
IRF5-CPP5 (0.62-50 μM) concentration-dependently inhibits CpGA-induced IFNα production in human primary BDCA2+ CD123+ pDCs[1].
IRF5-CPP5 (0.62-16.07 μM; 30 min) concentration-dependently inhibits SLE serum-induced IRF5 and phosphorylated IRF5 (pSer462) nuclear translocation in human primary CD14+ monocytes, CD19+ B cells, and BDCA2+ CD123+ pDCs, without altering total pIRF5 levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:THP-1 human monocytic cells
-
Concentration:1, 10 μM
-
Incubation Time:1 h
-
Result:Reduced (IRF5)2 levels.
Chemical Information
-
CAS No. 1601299-92-6
-
Appearance Solid
-
Molecular Weight 3294.95
-
Formula C160H245N37O36S
-
Color White to off-white
-
Sequence
Met-Ala-Asn-Leu-Gly-Tyr-Trp-Leu-Leu-Ala-Leu-Phe-Val-Thr-Tyr-Trp-Thr-Asp-Leu-Gly-Leu-Val-Lys-Lys-Arg-Pro-Lys-Pro
-
Sequence Shortening
MANLGYWLLALFVTYWTDLGLVKKRPKP
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (15.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.3035 mL | 1.5175 mL | 3.0349 mL | 7.5874 mL |
| 5 mM | 0.0607 mL | 0.3035 mL | 0.6070 mL | 1.5175 mL | |
| 10 mM | 0.0303 mL | 0.1517 mL | 0.3035 mL | 0.7587 mL | |
| 15 mM | 0.0202 mL | 0.1012 mL | 0.2023 mL | 0.5058 mL |